Introduction
============

Nasopharyngeal carcinoma (NPC) is a relatively rare disease in South Korea, and accounts for 7.2% to 23.1% of head and neck cancers \[[@b1-crt-2015-265],[@b2-crt-2015-265]\]. According to the Korean National Cancer Registry Report in 2011, its incidence in South Korea was 0.8 per 100,000 \[[@b3-crt-2015-265]\], lower than in endemic areas, such as southern China, southeast Asia, and north Africa, but higher than that of Western countries \[[@b2-crt-2015-265],[@b4-crt-2015-265]\]. NPC in endemic areas differs from Western NPC in that more than 90% of patients have non-keratinizing and undifferentiated carcinoma, which is more frequently related to Epstein-Barr virus (EBV) \[[@b1-crt-2015-265]\]. Although South Korea is a non-endemic area, some clinicopathologic characteristics of NPC are shared with NPC in endemic areas, including strong relation with EBV and a lower prevalence of keratinizing carcinoma than in Western countries \[[@b1-crt-2015-265],[@b2-crt-2015-265]\].

NPC is usually considered unresectable because of its anatomical location, thus radiation therapy (RT) plays a major role in its treatment \[[@b5-crt-2015-265],[@b6-crt-2015-265]\]. The current standard treatment strategy for locally advanced NPC is concurrent chemoradiotherapy (CCRT) with or without adjuvant chemotherapy, which was determined based on the superior results of randomized trials comparing RT alone and CCRT \[[@b7-crt-2015-265]-[@b9-crt-2015-265]\]. However, even when treated with CCRT, 3-year progression-free survival (PFS) is still only around 70% \[[@b7-crt-2015-265],[@b8-crt-2015-265]\]. Recent advances in RT technology, such as intensity-modulated radiation therapy (IMRT), make it possible to increase the radiation dose with the same or lower toxicity and achieve higher local control rates \[[@b5-crt-2015-265],[@b10-crt-2015-265]\]. In addition, because of the high rate of distant metastasis in NPC patients, there is a resurgence of interest in adjuvant and neoadjuvant chemotherapy (NCT) for advanced NPC in combination with CCRT. However, because of the diverse chemotherapy regimens, schedules, and mixed results reported, it is difficult to determine whether adjuvant chemotherapy or NCT can improve treatment outcome in NPC \[[@b5-crt-2015-265],[@b11-crt-2015-265]-[@b16-crt-2015-265]\].

In this study, we compared the treatment results and toxicities of CCRT alone (CRT arm) and NCT followed by CCRT (NCT arm) in primary NPC patients.

Materials and Methods
=====================

1. Patients
-----------

To review the NPC patterns of care and treatment outcomes in South Korea, a multi-institutional retrospective study (Korean Radiation Oncology Group \[KROG\] 11-06) was conducted through the Head and Neck Committee of Korean Society of Radiation Oncology (KOSRO). Data of 1474 primary NPC patients treated at 15 institutions in South Korea between September 1988 and October 2011 were collected. Clinical and pathological data were collected from medical records. All patients satisfied the following criteria: (1) biopsy-proven NPC; (2) stage I to IVb according to the American Joint Committee on Cancer (AJCC) cancer staging, 6th edition; (3) age over 18 years; and (4) Eastern Cooperative Oncology Group system (ECOG) performance status (PS) ≤ 2. Patients who had undergone previous surgery, radiotherapy to the head and neck, and those with distant metastasis before treatment initiation were excluded.

Prior to patient enrollment, institutional review board approval was obtained at each participating center and data were transferred to the KROG Data Center (National Cancer Center, Goyang, Korea). Radiotherapy, chemotherapy, toxicity, recurrence, and survival reports of all patients were reviewed according to a centralized quality-assurance program.

For this study, we selected 583 patients who satisfied the following inclusion criteria: (1) stage II to IVb by the AJCC cancer staging, 6th edition; (2) treated by CCRT alone or NCT followed by CCRT; and (3) non-receipt of any type of adjuvant chemotherapy after CCRT. Of these 583 patients, 15 patients with insufficient data for analysis of treatment outcome were excluded. The remaining 568 patients were finally included in the analysis, 380 patients were included in the CRT arm and 188 patients in the NCT arm.

2. Patient selection using the propensity score matching method
---------------------------------------------------------------

Because parts of the baseline characteristics between the CRT and NCT arm were statistically different, including histologic type, hospital size, and RT techniques ([Table 1](#t1-crt-2015-265){ref-type="table"}), the propensity score matching (PSM) method was used to control the imbalance. Nine covariates were entered in the propensity model, including age, sex, hospital size, ECOG PS, histologic type, T stage, N stage, RT technique, and the CCRT regimen. Propensity scores were calculated using a non-parsimonious multivariable logistic regression model to estimate the conditional probability. Then a 1:1 match between the CRT and NCT arm was performed using the nearest available neighbor matching. After PSM, 150 pairs of patients were matched successfully, and 300 patients were included for analysis.

3. Study endpoints and statistical analysis
-------------------------------------------

We analyzed the patients and treatment characteristics, compliances, toxicities, and treatment outcomes. Histologic type was defined according to the World Health Organization (WHO) classification 2005 \[[@b17-crt-2015-265]\]. Tumor responses were recorded according to WHO criteria \[[@b18-crt-2015-265]\]. Acute and late treatment toxicities were assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) ver. 3.0 \[[@b19-crt-2015-265]\]. Only the incidences of toxicities ≥ grade 3 were recorded.

Overall survival (OS) was defined as the time from pathologic diagnosis of NPC to any cause of death; all deaths from any cause were counted as events and patients who remained alive were treated as censored at the date of last follow-up. Disease-free survival (DFS) was defined as time from pathologic diagnosis to time of first failure at any site or any death. Locoregional failure-free survival (LRFFS) and distant failure-free survival (DFFS) were also analyzed, and were defined as any recurrence in the nasopharyngeal and/or cervical region or any failure at a distant site. Survival proportions were estimated using the Kaplan-Meier method.

Standardized differences were estimated for all baseline covariates before and after matching to assess pre-match imbalance and post-match balance. In the matched data, paired comparisons were performed using McNemar's test for binary variables and Wilcoxon signed rank test for continuous variables. The log-rank test and the Cox proportional hazards model were used to identify prognostic factors independently associated with survival and to estimate hazard ratios (HR). Two-sided p-values of \< 0.05 were considered statistically significant. Statistical analyses were performed using the software package SPSS ver. 21.0 (SPSS Inc., Chicago, IL) or R software ver. 2.15.3 (R Foundation for Statistical Computing, Vienna, Austria; <http://www.r-project.org>).

Results
=======

1. Patients and treatment characteristics
-----------------------------------------

A summary of patient and treatment characteristics before and after PSM is shown in [Table 1](#t1-crt-2015-265){ref-type="table"}. Of 300 patients selected after PSM, there were 222 male patients (74.0%) with a median age of 51 years (range, 19 to 77 years). The ECOG PS were 0-1 in 293 patients (97.6%), and 2 in only seven patients (2.3%). WHO type I (keratinizing carcinoma) tumors were found in 32 patients (10.7%), and were evenly distributed after PSM. The AJCC tumor stage was II in 26 patients (8.7%), III in 156 patients (52.0%), and IV in 118 patients (39.3%).

More patients in the NCT arm were treated with IMRT at small hospitals before PSM of which \"small\" means the average number of daily treated RT patients is under 100. After PSM, patients were evenly distributed, and 191 patients (63.7%) were treated with IMRT. The most commonly used chemotherapy regimen during the CCRT was cisplatin alone for 257 patients (85.7%). During NCT, taxane combined with cisplatin or 5-fluorouracil (5-FU), or both was most frequently used in 109 patients (62.7%). The other 41 patients (27.3%) received a non-taxane containing regimen during NCT.

2. Response and survival
------------------------

Tumor response data were collected only after completion of CCRT, and not after completion of NCT. It was evaluated in 290 patients (96.7%) after median 1.4 months follow-up (range, 0.1 to 39.0 months), and showed similar results between groups with no statistical difference (p=0.180). Complete response was achieved in 87 patients (60.0%) in the CRT arm, and 92 patients (63.4%) in the NCT arm. Objective response (complete or partial response) was achieved in 140 patients (96.6%) in the CRT arm, and 142 patients (97.9%) in the NCT arm. Progressive disease was found in two patients (1.4%), and both patients were in the NCT arm and had stage IV disease.

The OS, DFS, LRFFS, and DFFS between treatment arms are shown in [Fig. 1](#f1-crt-2015-265){ref-type="fig"} after a median follow-up of 35.9 months (range, 6.4 to 18.2 months) in the CRT arm, and 33.8 months (range, 6.4 to 152.6 months) in the NCT arm. The 5-year LRFFS was 85% in the CRT arm and 72% in the NCT arm, which was a statistically significant difference (p=0.014). Compared to LRFFS, lower 5-year DFFS was observed in the CRT arm compared with the NCT arm (65% vs. 76%); however, it was not statistically significant (p=0.390). No difference in OS and DFS was observed between the CRT and NCT arm. The 5-year OS and DFS were 72.1%, 52.2% in the CRT arm, and 81.1%, 57.1% in the NCT arm, respectively (p=0.340 and p=0.978, respectively).

3. Prognostic factors affecting survival
----------------------------------------

The results of multivariate analysis of the prognostic factors on survival are shown in [Table 2](#t2-crt-2015-265){ref-type="table"}. The T and N stage were significant factors affecting the survival. The T stage affected not only the LRFFS but also the DFFS, DFS, and OS, while the N-stage affected the DFFS and DFS only. The difference of LRFFS between treatment arms also showed statistical significance in multivariate analysis with HR of 2.21 (95% confidence interval \[CI\], 1.19 to 4.12; p=0.012). Other factors including sex, ECOG PS, WHO histology, and RT method did not show statistical significance in multivariate analysis.

4. Subgroup analysis
--------------------

In subgroup analysis by sex (male vs. female), PS (ECOG 0-1 vs. 2), histology (WHO type I vs. type II), the results of survival outcome between the CRT and NCT arm were similar. However, the results were different in AJCC stage IV subgroup and in patients younger than 60 years ([Table 3](#t3-crt-2015-265){ref-type="table"}). In AJCC stage IV patients (59 patients in each arm), the LRFFS, PFS, and OS did not differ between two arms. However, better 5-year DFFS was observed in the NCT arm compared to the CRT arm (47.3% vs. 75.8%) even though it did not reach statistical significance (p=0.088). In young patients under 60 years, no negative effect of NCT on LRFFS was observed (p=0.314). Therefore, in patients younger than 60 years with AJCC stage IV disease, the adjusted HR for DFFS was 0.46 (95% CI, 0.21 to 0.99; p=0.049). The DFS also favored NCT arms in these patients with HR of 0.56 (95% CI, 0.30 to 1.02) with marginal significance (p=0.058). However, the OS was not different. The survival outcomes of these patients are shown in [Fig. 2](#f2-crt-2015-265){ref-type="fig"}.

5. Compliance and toxicity
--------------------------

Because only patients who had completed their RT schedule were selected after PSM, the compliance was analyzed on the whole patient cohort and is shown in [Table 4](#t4-crt-2015-265){ref-type="table"}. Of the 568 patients, 15 patients (2.6%) did not receive the planned RT dose and treatment was interrupted. Seven of these 15 patients were in the CRT arm, and eight were in the NCT arm. A higher percentage was observed in the NCT arm (4.3% vs. 1.8%), but without statistical significance (p=0.091). The reasons for RT interruption were poor general condition (9 patients), severe mucositis (2 patients), patient refusal (2 patients), and renal failure (1 patient). Durations of RT were similar in the two arms with an average of 53.5 days in the CRT arm and 52.8 days in the NCT arm for the entire cohort (p=0.621). However, in the PSM cohort, the average RT duration was 3.9 days longer in the NCT arm (50.0 vs. 53.9 days, p=0.018).

The chemotherapy schedule during CCRT was interrupted in 94 patients (16.5%), 61 patients in the CRT arm and 33 patients in the NCT arm. Chemotherapy tolerance during CCRT was similar in the two arms for any chemotherapy regimen ([Table 4](#t4-crt-2015-265){ref-type="table"}). Five patients (2.7%) received only one cycle of the planned NCT course because of no response or progression in four patients and nephrotoxicity in one.

Acute and late toxicities are shown in [Table 5](#t5-crt-2015-265){ref-type="table"}. Toxicity was analyzed in the PSM cohort to balance the use of IMRT and the difference of chemotherapy regimen. The most frequent ≥ grade 3 acute toxicities were neutropenia and mucositis. Incidences of ≥ grade 3 acute toxicity showed no difference between the treatment arms. However, higher incidence of ≥ grade 4 hematologic toxicity was observed in the NCT arm (3.3% vs. 0.7%). The most frequent late toxicity was xerostomia, followed by soft tissue fibrosis, radiation necrosis, and ototoxicity. However, the most fatal toxicities were radiation necrosis and neutropenia. Overall, treatment-related death occurred in seven patients (2.3%). No difference in late toxicity was observed between treatment arms.

Discussion
==========

To improve the treatment outcomes of NPC, the addition of adjuvant chemotherapy or NCT to CCRT has been widely studied \[[@b5-crt-2015-265]\]. NCT is believed to be superior to adjuvant chemotherapy in some theoretical aspects: (1) compliance with the entire course of chemotherapy is higher for NCT; (2) penetration of chemotherapeutic agents into tumor tissues might be limited due to the disruption of native blood vessels after RT; and (3) NCT might kill subclinical micrometastases before definitive local treatment \[[@b5-crt-2015-265],[@b20-crt-2015-265]\]. For these reasons, NCT has been an attractive strategy for many researchers.

Before the Intergroup 0099 study, which showed superior results for CCRT as compared with RT alone \[[@b7-crt-2015-265]\], several studies compared NCT followed by RT and RT alone. Although a reduction in relapse-free and disease-specific survival was observed with NCT in some studies, no differences in OS or treatment failure pattern were observed \[[@b21-crt-2015-265],[@b22-crt-2015-265]\].

After CCRT became the standard treatment for advanced NPC, there were questions with regard to whether addition of NCT to CCRT could improve outcomes, and, as a result, several phase II trials were conducted. Hui et al. \[[@b11-crt-2015-265]\] reported on a comparative randomized phase II study on NCT with docetaxel and cisplatin (TP) followed by CCRT versus CCRT alone. Three-year DFS was not significantly different (88.2% in the NCT arm and 59.5% in the CRT arm, p=0.12). However, 3-year OS was statistically superior in the NCT arm (94.1% vs. 67.7%).

The Hellenic Cooperative Oncology Group (HeCOG) also reported the results of a comparative phase II study on NCT with a cisplatin/epirubicin/paclitaxel regimen followed by CCRT versus CCRT alone \[[@b14-crt-2015-265]\]. In analysis of the data of 141 patients, no difference in terms of compliance, response, 3-year DFS and OS was observed between the two arms.

A meta-analysis on 11 studies conducted by Liang et al. \[[@b15-crt-2015-265]\], which included 1096 NPC patients, compared the results of NCT followed by CCRT versus CCRT with or without adjuvant chemotherapy. This study also showed that NCT followed by CCRT did not significantly improve OS, LRFFS, or DFFS.

In the current study, we also failed to demonstrate a better outcome for NCT versus CCRT alone. Although the DFFS, DFS, and OS did not differ between groups, lower LRFFS was observed in the NCT arm. This result seems to reflect the theoretical disadvantages of NCT. The disadvantages of NCT include the selection of resistant tumor cell clones, triggering accelerated repopulation, and reduced compliance and increased toxicity during CCRT.

In our study, even though the toxicities were similar between the two arms, RT was interrupted more frequently in the NCT arm (4.3%) than in the CRT arm (1.8%), and the overall treatment time of RT was also longer in the NCT arm in the PSM cohort. In our study, in comparison of the local control rate according to RT duration, significantly lower LRFFS was observed in patients with RT duration longer than 50 days (82.8% vs. 73.3%, p=0.034). The advantage of NCT by reducing the distant failure was only observed in stage IV disease patients and those younger than 60 years. This result of subgroup analysis was consistent with that of the study reported by Zhang et al. \[[@b23-crt-2015-265]\]. They also conducted a PMS study of NPC patients in China, which showed improved DFFS only in T4N1-2 or N3 patients (86.1% vs. 74.9%, p=0.034), favoring NCT.

However, there are some limitations of our study that warrant consideration. First, the heterogeneous NCT regimen could diminish the positive effect of NCT. Non-taxane containing regimen was also used in 27.3% of patients, which was unfavorable if we consider the recent impressive outcomes by addition of taxane to the NCT regimens. In the EORTC 24971/TAX 323 study, triple combinations of docetaxel, cisplatin, and 5-FU (TPF) showed superior PFS and OS rates compared with cisplatin and 5-FU in other head and neck cancers \[[@b24-crt-2015-265]\]. Based on these findings, Ekenel et al. \[[@b13-crt-2015-265]\] used TP for the NCT regimen in NPC patients, and reported a 3-year OS of 94.9% and a PFS of 84.7%. Bae et al. \[[@b12-crt-2015-265]\], who also reported the results of NCT using the TPF regimen followed by CCRT in Korea, achieved 3-year OS and PFS rates of 86.1% and 75.6%, respectively \[[@b12-crt-2015-265]\], which were slightly lower than results obtained in endemic areas, but were nevertheless remarkable.

The second limitation of our study was the relatively imperfect data on toxicity. This was due to the retrospective nature of data collection from several institutions, and it resulted in comparative low toxicity rates than other literatures. However, similar toxicity rates between two treatment arms have also been reported in other studies. The HeCOG group study reported no significant differences in acute toxicities after CCRT \[[@b14-crt-2015-265]\], even though thrombocytopenia was more common in the NCT arm and dermatitis was more common in the CRT arm. However, the rates of all other toxicities were similar in both arms. In a meta-analysis conducted by Liang et al. \[[@b15-crt-2015-265]\], the toxicity results showed that the risk ratio of grade 3-4 neutropenia was 1.90 (95% CI, 1.24 to 2.92) in favor of the CRT arm rather than the NCT arm. However, other toxicities were similar.

Conclusion
==========

In conclusion, this study did not show the superiority of NCT followed by CCRT over CCRT alone. Because NCT could increase the risk of locoregional recurrences, it can only be considered in selected young patients with advanced stage IV disease. The role of NCT in addition to CCRT remains to be defined and is currently not the standard of care. The results of phase III trials are needed in order to draw a firm conclusion.
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###### 

Baseline patient characteristics in the pre- and post-propensity score matching cohort

  Characteristic        Before propensity score matching   After propensity score matching                                          
  --------------------- ---------------------------------- --------------------------------- ---------- -------------- ------------ ----------
  **Sex**                                                                                                                           
   Male                 266 (70.0)                         144 (76.6)                        0.099      111 (74.0)     111 (74.0)   \> 0.999
   Female               114 (30.0)                         44 (23.4)                                    39 (26.0)      39 (26.0)    
  **Age**                                                                                                                           
   Median (range, yr)   52 (19-86)                         50 (20-73)                        0.223      51.5 (19-77)   50 (19-72)   0.648
   Mean±SD              51.4±13.1                          50.0±12.1                                    50.8±13.2      50.5±11.6    
  **ECOG PS**                                                                                                                       
   0                    65 (17.1)                          34 (18.1)                         0.539      27 (18.0)      25 (16.7)    0.963
   1                    303 (79.7)                         151 (80.3)                                   119 (79.3)     122 (81.3)   
   2                    12 (3.2)                           3 (1.6)                                      4 (2.7)        3 (2.0)      
  **WHO histology**                                                                                                                 
   I                    77 (20.3)                          17 (9.0)                          \< 0.001   15 (10.0)      17 (11.3)    0.502
   IIa                  108 (28.4)                         75 (39.9)                                    59 (39.3)      58 (38.7)    
   IIb                  187 (49.2)                         84 (44.7)                                    70 (46.7)      71 (47.3)    
   Not classified       8 (2.1)                            12 (6.4)                                     6 (4.0)        4 (2.7)      
  **T stage**                                                                                                                       
   1                    95 (25.0)                          54 (28.7)                         0.308      38 (25.3)      40 (26.7)    0.389
   2                    102 (26.8)                         39 (20.7)                                    34 (22.7)      34 (22.7)    
   3                    86 (22.6)                          39 (20.7)                                    36 (24.0)      35 (23.3)    
   4                    97 (25.5)                          56 (29.8)                                    42 (28.0)      41 (27.3)    
  **N stage**                                                                                                                       
   0                    44 (11.6)                          16 (8.5)                          0.366      15 (10.0)      13 (8.7)     0.410
   1                    104 (27.4)                         50 (26.6)                                    42 (28.0)      41 (27.3)    
   2                    172 (45.3)                         98 (52.1)                                    71 (47.3)      75 (50.0)    
   3                    60 (15.8)                          24 (12.8)                                    22 (14.7)      21 (14.0)    
  **AJCC stage**                                                                                                                    
   II                   38 (10.0)                          13 (6.9)                          0.480      14 (9.3)       12 (8.0)     0.914
   III                  194 (51.1)                         99 (52.7)                                    77 (51.3)      79 (52.7)    
   IV                   148 (38.9)                         76 (40.4)                                    59 (39.3)      59 (39.3)    
  **Hospital size**                                                                                                                 
   Large                264 (69.5)                         104 (55.3)                        0.001      97 (64.7)      93 (62.0)    0.637
   Small                116 (30.5)                         84 (44.7)                                    53 (35.3)      57 (38.0)    
  **RT method**                                                                                                                     
   Non-IMRT             231 (60.8)                         63 (33.5)                         \< 0.001   52 (34.7)      57 (38.0)    0.456
   IMRT                 149 (39.2)                         125 (66.5)                                   98 (65.3)      93 (62.0)    
  **CRT regimen**                                                                                                                   
   Cisplatin alone      322 (84.7)                         159 (84.6)                        0.883      131 (87.3)     126 (84.0)   0.411
   Combined             58 (15.3)                          29 (15.4)                                    19 (12.7)      24 (16.0)    
  **NCT regimen**                                                                                                                   
   FP                   \-                                 36 (19.1)                         N/A        \-             32 (21.3)    N/A
   F or P+taxane        \-                                 64 (34.0)                                    \-             61 (40.7)    
   FP+taxane            \-                                 78 (41.4)                                    \-             48 (32.0)    
   Other                \-                                 10 (5.3)                                     \-             9 (6.0)      

Values are presented as number (%) unless otherwise indicated. CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant chemotherapy arm; SD, standard deviation; ECOG PS, Eastern Cooperative Oncology Group performance status; WHO, World Health Organization; AJCC, American Joint Committee on Cancer; RT, radiation therapy; IMRT, intensity-modulated radiotherapy; F, 5-fluorouracil; P, cisplatin; N/A, not assessed.

###### 

Multivariate analysis of prognostic factors in the propensity-matched cohort

  Factor                          Overall survival   Disease-free survival   Locoregional failure-free survival   Distant failure-free survival                                                 
  ------------------------------- ------------------ ----------------------- ------------------------------------ ------------------------------- ------------------ ------- ------------------ -------
  Treatment arm (CRT vs. NCT)     0.74 (0.53-1.30)   0.297                   1.02 (0.70-1.47)                     0.939                           2.21 (1.19-4.12)   0.012   0.84 (0.52-1.38)   0.844
  Sex (male vs. female)           1.46 (0.7-2.75)    0.246                   0.90 (0.58-1.41)                     0.648                           1.25 (0.65-2.42)   0.503   0.61 (0.31-1.18)   0.140
  Age (\< 60 yr vs. ≥ 60 yr)      1.02 (1.00-1.05)   0.087                   1.01 (0.99-1.03)                     0.258                           1.03 (1.00-1.05)   0.069   1.00 (0.98-1.02)   0.841
  ECOG PS (0-1 vs. 2)             0.63 (0.08-4.91)   0.662                   1.26 (0.45-3.55)                     0.662                           2.13 (0.48-9.48)   0.319   0.92 (0.22-3.90)   0.913
  WHO histology (I vs. II)        1.32 (0.55-3.19)   0.535                   1.21 (0.68-2.15)                     0.528                           1.10 (0.45-2.67)   0.830   1.81 (0.76-4.30)   0.180
  T stage (1-2 vs. 3-4)           2.54 (1.38-4.70)   0.003                   2.28 (1.53-3.39)                     \< 0.001                        2.16 (1.16-4.01)   0.015   2.11 (1.26-3.53)   0.005
  N stage (0-1 vs. 2-3)           1.56 (0.85-2.89)   0.153                   2.00 (1.30-3.08)                     0.002                           1.47 (0.76-2.82)   0.252   2.30 (1.29-4.10)   0.005
  RT method (non-IMRT vs. IMRT)   0.93 (0.52-1.69)   0.819                   1.00 (0.67-1.49)                     0.996                           0.99 (0.53-1.85)   0.970   0.94 (0.56-1.58)   0.821

HR, hazard ratio; CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant chemotherapy arm; ECOG PS, Eastern Cooperative Oncology Group performance status; WHO, World Health Organization; RT, radiation therapy; IMRT, intensity-modulated radiotherapy.

###### 

Subgroup analysis by prognostic factors in the propensity-matched cohort

  Factor (CRT vs. NCT arm)                         Overall survival   Disease-free survival   Locoregional failure-free survival   Distant failure-free survival                                                  
  ------------------------------------------------ ------------------ ----------------------- ------------------------------------ ------------------------------- ------------------- ------- ------------------ -------
  **Age**                                                                                                                                                                                                         
   \< 60 yr (116 vs. 110)                          0.78 (0.38-1.58)   0.486                   0.79 (0.50-1.24)                     0.302                           1.48 (0.69-3.19)    0.314   0.64 (0.36-1.15)   0.138
   ≥ 60 yr (44 vs. 40)                             0.80 (0.32-2.02)   0.804                   1.65 (0.85-3.21)                     0.138                           4.04 (1.33-12.26)   0.014   1.48 (0.58-3.76)   0.407
  **AJCC stage**                                                                                                                                                                                                  
   II-III (91 vs. 91)                              0.45 (1.67-1.21)   0.116                   1.28 (0.74-2.19)                     0.378                           3.34 (1.33-8.37)    0.010   1.06 (0.53-2.11)   0.873
   IV (59 vs. 59)                                  1.08 (0.53-2.16)   0.840                   0.80 (0.47-1.34)                     0.390                           1.49 (0.62-3.57)    0.377   0.54 (0.27-1.09)   0.088
  **Age \< 60 yr and AJCC stage IV (44 vs. 46)**   0.81 (0.33-2.02)   0.652                   0.56 (0.30-1.02)                     0.058                           1.06 (0.36-3.08)    0.918   0.46 (0.21-0.99)   0.049

CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant chemotherapy arm; HR, hazard ratio; AJCC, American Joint Committee on Cancer.

###### 

Radiotherapy and chemotherapy compliance in the entire cohort

  Type of treatment              CRT (n=380)     NCT (n=188)     p-value
  ------------------------------ --------------- --------------- ---------
  **Radiation interruption**     7 (1.8)         8 (4.3)         0.091
   Duration, mean (range, day)                                   
    Entire cohort                53.5 (17-165)   52.8 (13-158)   0.621
    PSM cohort                   50.0 (31-98)    53.9 (34-117)   0.018
  **Chemotherapy during CRT**                                    
   Total interruption            61 (16.1)       33 (17.6)       0.651
   Cisplatin weekly                                              
    1-4 cycles                   24 (18.8)       23 (21.9)       0.550
    ≥ 5 cycles                   104 (81.2)      82 (78.1)       
   Cisplatin, every 3 wk                                         
    1 cycle                      17 (8.9)        3 (5.7)         0.447
    ≥ 2 cycles                   174 (91.1)      50 (94.3)       
   Platinum+5-FU or taxane                                       
    1-2 cycles                   15 (40.5)       5 (35.7)        0.752
    ≥ 3 cycles                   22 (59.5)       9 (64.3)        
  **Chemotherapy during NCT**                                    
    1 cycle                      \-              5 (2.7)         \-
    2 cycles                     \-              35 (22.9)       
    ≥ 3 cycles                   \-              148 (77.1)      

Values are presented as number (%) unless otherwise indicated. CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant chemotherapy arm; PSM, propensity score matching; 5-FU, 5-fluorouracil.

###### 

Grade 3 or higher acute and late toxicity in the propensity-matched cohort

  Type of toxicity                 CRT (n=150)   NCT (n=150)   p-value
  -------------------------------- ------------- ------------- ----------
  **Acute toxicity (grade 3/4)**                               
   Hematologic                                                 
    Grade 3                        17 (11.3)     18 (12.0)     0.857
    Grade 4                        1 (0.7)       5 (3.3)       0.214
   Anorexia/Nausea/Vomiting        5 (3.3)       2 (1.3)       0.448
   Mucositis/Odynophagia           27 (18.0)     29 (19.3)     0.767
   Dermatitis                      4 (2.7)       6 (4.0)       0.750
   Xerostomia                      4 (2.7)       4 (2.7)       \> 0.999
   Any acute toxicity              57 (38.0)     59 (39.3)     0.813
  **Late toxicity (grade 3/4)**                                
   Soft tissue fibrosis            5 (3.3)       3 (2.0)       0.723
   Radionecrosis/Neuropathy        2 (1.3)       1 (0.7)       \> 0.999
   Xerostomia                      6 (4.0)       7 (4.7)       0.777
   Ototoxicity                     1 (0.7)       2 (1.3)       \> 0.999
   Any late toxicity               14 (9.3)      13 (8.7)      0.840
  **Grade 5 toxicity**                                         
   Radionecrosis/Neuropathy        0             2 (1.3)       0.498
   Neutropenia/Infection           1 (0.7)       0             \> 0.999
   Not reported                    2 (1.3)       2 (1.3)       \> 0.999
   Any grade 5 toxicity            3 (2.0)       4 (2.7)       \> 0.999

Values are presented as number (%). Treatment toxicities were assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (ver. 3.0). CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant chemotherapy arm.
